Ventus Therapeutics, Inc. announced today that the company has entered into an exclusive worldwide license agreement with Novo Nordisk A/S to develop and commercialize candidates from Ventus’ portfolio of peripherally-restricted NLRP3 inhibitors.
Read MoreIn celebration of Global Biotech Week, today at the national BIONATION 2022 conference, the leaders of Genome Canada and adMare BioInnovations announced a new strategic partnership to support the translation of genomics research into commercialization opportunities in healthcare.
Genomics-enabled precision health tools are speeding up diagnoses and improving health outcomes and disease management for Canadians.
